Harrow Health Inc - Asset Resilience Ratio
Harrow Health Inc (HROW) has an Asset Resilience Ratio of 0.83% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see HROW current and non-current assets.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Harrow Health Inc's Asset Resilience Ratio has changed over time. Read Harrow Health Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Harrow Health Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See how many days can Harrow Health Inc fund operations to measure how many days the company can operate on defensive assets alone.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.85 Million | 0.83% |
| Total Liquid Assets | $2.85 Million | 0.83% |
Asset Resilience Insights
- Limited Liquidity: Harrow Health Inc maintains only 0.83% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Harrow Health Inc Industry Peers by Asset Resilience Ratio
Compare Harrow Health Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Mankind Pharma Ltd
NSE:MANKIND |
Drug Manufacturers - Specialty & Generic | 8.83% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Harrow Health Inc (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Harrow Health Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.88% | $3.41 Million | $388.97 Million | -1.91pp |
| 2023-12-31 | 2.78% | $8.68 Million | $311.75 Million | -0.77pp |
| 2022-12-31 | 3.56% | $5.59 Million | $157.02 Million | -5.09pp |
| 2021-12-31 | 8.65% | $8.50 Million | $98.33 Million | -41.19pp |
| 2020-12-31 | 49.84% | $28.64 Million | $57.47 Million | +7.19pp |
| 2019-12-31 | 42.65% | $25.20 Million | $59.09 Million | -0.67pp |
| 2018-12-31 | 43.32% | $21.42 Million | $49.45 Million | +42.48pp |
| 2017-12-31 | 0.84% | $200.00K | $23.92 Million | +0.10pp |
| 2016-12-31 | 0.73% | $200.00K | $27.25 Million | -0.33pp |
| 2015-12-31 | 1.06% | $150.00K | $14.13 Million | -0.41pp |
| 2014-12-31 | 1.47% | $150.26K | $10.24 Million | +1.15pp |
| 2013-12-31 | 0.32% | $50.00K | $15.76 Million | -- |
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, in… Read more